Total Payments
$2,989
2024 Payments
$1,194
Companies
46
Transactions
146
Medicare Patients
19,892
Medicare Billing
$8.0M
Payment Breakdown by Category
Food & Beverage$2,890 (96.7%)
Education$98.92 (3.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,890 | 144 | 96.7% |
| Education | $98.92 | 2 | 3.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $237.40 | 2 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $230.19 | 11 | $0 (2024) |
| ABBVIE INC. | $170.93 | 10 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $166.53 | 12 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $159.96 | 6 | $0 (2024) |
| Tempus AI, Inc | $156.59 | 14 | $0 (2024) |
| GlaxoSmithKline, LLC. | $137.66 | 5 | $0 (2024) |
| GENZYME CORPORATION | $135.40 | 6 | $0 (2024) |
| Janssen Biotech, Inc. | $121.77 | 14 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $117.29 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,194 | 68 | Tempus AI, Inc ($156.59) |
| 2023 | $563.52 | 25 | Regeneron Healthcare Solutions, Inc. ($78.93) |
| 2022 | $477.84 | 20 | Seagen Inc. ($87.00) |
| 2021 | $221.46 | 11 | Ipsen Biopharmaceuticals, Inc ($43.84) |
| 2020 | $133.61 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($117.29) |
| 2019 | $44.21 | 3 | JAZZ PHARMACEUTICALS INC. ($19.24) |
| 2018 | $121.87 | 2 | Janssen Scientific Affairs, LLC ($108.24) |
| 2017 | $232.55 | 15 | Janssen Scientific Affairs, LLC ($129.16) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $39.35 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: Oncology | ||||||
| 11/16/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Oncology | ||||||
| 11/15/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $30.54 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $29.79 | General |
| Category: NONE | ||||||
| 10/30/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Oncology | ||||||
| 10/25/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $11.25 | General |
| 10/23/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $21.93 | General |
| Category: Oncology | ||||||
| 10/16/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/09/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Oncology | ||||||
| 10/03/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/03/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $3.41 | General |
| Category: NONE | ||||||
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: NONE | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Oncology | ||||||
| 09/13/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.71 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 80 | 4,911 | 140,067 | $11.4M | $2.4M |
| 2022 | 87 | 5,007 | 151,108 | $9.5M | $1.9M |
| 2021 | 87 | 5,085 | 147,411 | $10.3M | $2.2M |
| 2020 | 84 | 4,889 | 105,738 | $7.5M | $1.6M |
Total Patients
19,892
Total Services
544,324
Medicare Billing
$8.0M
Procedure Codes
338
All Medicare Procedures & Services
338 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 38 | 17,200 | $2.3M | $740,611 | 31.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 23 | 14,460 | $1.1M | $341,652 | 31.0% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 17 | 9,000 | $1.1M | $340,433 | 30.0% |
| J9228 | Injection, ipilimumab, 1 mg | Office | 2023 | 11 | 1,650 | $687,300 | $216,209 | 31.5% |
| J9173 | Injection, durvalumab, 10 mg | Office | 2023 | 13 | 2,880 | $567,450 | $178,808 | 31.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 26 | 2,864 | $671,270 | $96,690 | 14.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 313 | 694 | $255,392 | $60,804 | 23.8% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 75 | 207 | $571,734 | $56,227 | 9.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 246 | 491 | $347,137 | $47,383 | 13.6% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 16 | 1,771 | $274,505 | $43,836 | 16.0% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 28 | 456 | $614,688 | $40,019 | 6.5% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 70 | 96 | $165,312 | $32,235 | 19.5% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 14 | 1,200 | $217,200 | $27,256 | 12.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 1,500 | $98,280 | $27,097 | 27.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 22 | 8,209 | $164,180 | $19,180 | 11.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 11 | $52,822 | $12,201 | 23.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 385 | 940 | $60,160 | $9,664 | 16.1% |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | Office | 2023 | 27 | 53 | $37,100 | $9,425 | 25.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 387 | 1,113 | $22,260 | $9,341 | 42.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 140 | 200 | $62,600 | $9,178 | 14.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 115 | 141 | $35,250 | $8,933 | 25.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 33 | 20,910 | $104,550 | $8,335 | 8.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 378 | 1,011 | $36,396 | $7,598 | 20.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 43 | 47 | $50,149 | $7,549 | 15.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 93 | 152 | $52,288 | $7,330 | 14.0% |
About Dr. Thomas Gregory, M.D
Dr. Thomas Gregory, M.D is a Medical Oncology healthcare provider based in Tyler, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174566624.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Gregory, M.D has received a total of $2,989 in payments from pharmaceutical and medical device companies, with $1,194 received in 2024. These payments were reported across 146 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($2,890).
As a Medicare-enrolled provider, Gregory has provided services to 19,892 Medicare beneficiaries, totaling 544,324 services with total Medicare billing of $8.0M. Data is available for 4 years (2020–2023), covering 338 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Tyler, TX
- Active Since 06/13/2006
- Last Updated 07/08/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1174566624
Products in Payments
- DARZALEX (Biological) $262.63
- LIBTAYO (Biological) $179.85
- XT CDX (Device) $156.59
- EPKINLY (Drug) $153.94
- IMJUDO (Biological) $127.30
- ZEJULA (Drug) $118.46
- NINLARO (Drug) $117.29
- MONJUVI (Drug) $111.42
- VERZENIO (Drug) $80.92
- IMBRUVICA (Drug) $80.67
- SOMATULINE DEPOT (Drug) $68.81
- SARCLISA (Biological) $67.93
- COSELA (Drug) $67.01
- IMFINZI (Biological) $63.62
- OPDIVO (Biological) $60.27
- ULTOMIRIS (Biological) $59.70
- VONJO (Drug) $54.21
- ENHERTU (Drug) $53.08
- ELITEK (Biological) $47.58
- ZEPZELCA (Drug) $44.30
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.